Mimo

MIMO Biosciences is a spin-off company emerging from research outcomes obtained at CIMA Universidad de Navarra during the last twelve years . MIMO’s mission is to provide preclinical research services based on unique animal models that recapitulate a wide array of genetic alterations of different hematological malignancies including multiple myeloma and lymphomas.

These models, which can be customised to the needs of each client, have been generated through thoughtful scientific and clinical collaboration by Dr. Jose Angel Martinez-Climent and his research team.

MIMO brings together know-how, technology and animal models with the mission of providing preclinical services to academic and pharma partners in multiple myeloma (MM), lymphoma, and other related fields. With a highly qualified scientific and management team, MIMO has launched an ambitious program to develop newly designed, proprietary preclinical models of genetically diverse MM with multiple humanized targets. 

MIMO is also generating patient-derived xenograft (PDX) models from MM patient samples engrafted into IL6-secreting immunodeficient mice, reconstituted with a human immune system. 

Additionally, MIMO is expanding the generation of humanized mouse and PDX models for the principal B-cell lymphoma subtypes.